Abstract: Hydrophobic liquids are microencapsulated by an enteric matrix in an environment substantially free of organic solvents. The process includes forming an emulsion of the enteric material and hydrophobic liquid in water, titrating the emulsion with an acid to form a particulate precipitate and optionally coating the particulate with a combination of enteric material and plasticizer.

Abstract: The present invention is directed to a mixture of esters according to the general formula (I), R1—C(?O)—O—R2, wherein R1 is an alkyl moiety with 5 to 11 carbon atoms and wherein R2 is a an alkyl moiety with 8 to 18 carbon atoms and wherein the mixture comprises 10 or less than 10 weight-% of ester of the general formula (I) wherein R1 is an alkyl moiety with 9 or more carbon atoms, based on the total amount of esters according to formula (I). The invention is further directed to cosmetic and/or pharmaceutical compositions comprising such esters as well as to processes for the production of such esters.

Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.

Abstract: An agrochemical composition comprising a propylene glycol fatty acid monoester and fenbutatin oxide in a proportion of 1:150 to 150:1 in terms of a mass ratio (propylene glycol fatty acid monoester:fenbutatin oxide) shows an excellent control effect on pests, hyposensitive mites having reduced sensitivity to chemicals, eggs of mites, and pests other than mites in all stages of growth, even when the composition is applied in a small amount. A pest control method comprising applying the propylene glycol fatty acid monoester and fenbutatin oxide in a proportion of 1:150 to 150:1 in terms of a mass ratio (propylene glycol fatty acid monoester:fenbutatin oxide) to pests or a habitat of the pests also shows an excellent control effect.

Abstract: Compositions and methods for killing ectoparasites on a subject. Compositions containing a fatty acid ester, e.g., isopropyl myristate, effective for killing ectoparasites is described. Also described are compositions containing a fatty acid ester and a siloxane (e.g., decacyclomethicone). The compositions can also contain a mectin and/or a mycin, and S-methoprene. The compositions are useful against a variety of ectoparasites that afflict humans, animals, and plants, e.g., head lice, fleas, body lice, crab lice, scabies, ticks, and plant parasites.

Abstract: Methods and formulations for improving the sensory characteristics and stability of dietary fatty acids for use in beverages, liquid concentrates, or other formulations are disclosed.

Abstract: The present invention provides feed-through pesticide formulation suitable for hydrophobic active ingredients. The formulation comprises a hydrophobic active ingredient on a solid carrier, with a hydrophilic coating and an optional hydrophobic coating contacting the hydrophilic coating.

Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.

Abstract: Provided are compositions and methods for producing stable foods and beverages that contain high concentrations of additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.

Abstract: Biodegradable detergent compositions comprising enzymes and 1,3-propanediol are provided. The 1,3-propanediol in the composition is biologically derived and enhances the stability of the enzymes in the composition. The compositions also exhibit a low anthropogenic CO2 emission profile.

Abstract: Compositions that can include a carrier, targeting agent, and therapeutic agent are disclosed herein. The therapeutic agent may have a therapeutic activity such as inhibiting fibrosis within a target organ or tissue or inhibiting the growth of a cancer cell.

Abstract: Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.

Abstract: This invention relates to synergistic combinations of selected microbicides in combination with a second microbicide or formulation ingredient or raw material. The combinations have greater efficacy than would be expected from combinations of the individual components. The combinations include mixtures of (a) 5-Chloro-2-methyl-4-isothiazolin-3-one+2-Methyl-4-isothiazolin-3-one, (b) Methyl-4-isothiazolin-3-one, or (c) 1,2-Benzisothiazolin-3-one with one or more of a variety of other compounds.

Abstract: To provide an oil-in-water emulsion skin care cosmetic composition which, without the addition of a pharmaceutical agent and a film-forming agent or the like thereto, effects an excellent elastic or resilient feeling to skin and is excellent in non-stickiness and stability. An oil-in-water emulsion skin care cosmetic composition, comprising (a) a paraffin wax and/or a polyethylene wax, (b) a microcrystalline wax, and (c) an animal/plant-derived wax which contains, as the main ingredient thereof, an ester of a higher fatty acid having from 20 to 32 carbon atoms and an alcohol having from 28 to 34 carbon atoms, and has a melting point of from 75 to 100° C., in which the ratio of component (a) to component (b) is from 70/30 to 95/5 (by mass).

Abstract: The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.

Abstract: The aim of the present invention is to provide a fluid composition that can form a coating, said composition being characterized in that it contains, at least in a solvent medium, an effective amount of at least one natural virucide selected from among lauric acid, monolaurin, lactoferrin and essential oils having antiviral activity and/or one of the precursors thereof, said composition having a viscosity of 30 mPa·s to 40 Pa·s at room temperature and pressure.

Abstract: The present invention relates to pharmaceutical compositions comprising ester(s) of capsaicin and at least one other agent selected from salicylates, menthol, boswellic acids, DMSO, methyl sulfonylmethane, NSAIDs, corticosteroids, emu oil, opioid agonists and antagonists, NMDA antagonists, tramadol, hyaluronic acid, ?2? ligands, santalol, santalyl acetate, amyris alcohol, amyris acetate, aloe vera gel and aloe vera juice, for improved therapeutic properties. Further, the present invention relates to pharmaceutical compositions comprising high concentrations of ester(s) of capsaicin. Further, the present invention relates to a method of relieving pain due to various diseases in subjects by administering the pharmaceutical compositions of the invention.

Abstract: The present invention relates to a cleaning composition for removing cellular components from tissue for transplantation derived from humans and animals. More particularly, the present invention relates to a cleaning composition for treating tissue for transplantation comprising a polyoxyethyleneglycol C14-C20alkyl ether as a first protein solubilizing component, a C6-C8alkylphenol polyethoxylate as a first lipid solubilizing component, a C10-C16alkyl glycoside as a second protein solubilizing component and a C9-C12alkylphenoxy polyethoxy ethanol as a second lipid solubilizing component.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

Abstract: The emulsion composition of the present invention contains (A) 0.001 to 10 wt. % of an organic compound having two or more hydroxyl groups, an inorganic value of 220 to 450, and an organic value of 300 to 1,000; (B) 0.001 to 10 wt. % of an organic compound having one hydroxyl group, an inorganic value of 100 to 200, and an organic value of 280 to 700; (C) 0.001 to 10 wt. % of a compound represented by formula (2): wherein R1 is a C4 to C30 hydrocarbon group; Z is a methylene group, a methine group, or an oxygen atom; X1, X2, X3 is a hydrogen atom, a hydroxyl group, or an acetoxy group; X4 is a hydrogen atom, an acetyl group, or a glyceryl group; each of R2 and R3 a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; R4 is a C5 to C60 hydrocarbon group; and R5 is a hydrogen atom or a hydrocarbon group containing 1 to 30 carbon atoms in total; (D) 0.00012 to 10 wt.

Abstract: Embodiments of the present invention provide compositions for controlling a target pest including a first agent and a second agent comprising a pest control product or a signal cascade modulator, wherein the first agent and the second agent act synergistically to control the target pest. The first agent can be capable of interacting with a receptor in the target pest. The pest control product can have a first activity against the target pest when applied without the active agent and the compositions can have a second activity against the target pest; and the second activity can be greater than the first activity. Embodiments of the invention can include compositions that modulate the signal cascade initiated by the binding of ligands to, for example, cell surface receptors. Methods of screening such compositions are also disclosed.

Abstract: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.

Abstract: The present invention teaches a surfactant blend composition of at least one nonionic alkoxylate and at least one sugar-based surfactant, and its use as an adjuvant for pesticides. The pesticidal composition employing the surfactant blend composition of the invention realizes an efficacy that is unexpectedly superior to similar pesticidal compositions which employ only the individual surfactant components. The composition of the present invention is useful as a tank side additive, or as a component in herbicidal formulations. In addition the compositions of the present invention are useful as adjuvants for other pesticides, such as, fungicides, insecticides, plant growth regulators, acaracides and the like.

Abstract: In one aspect, an epidermal coolant dispensable by an aerosol container includes a phase change material that changes phase between about 28-degrees and 40-degrees Celsius. The coolant also includes a solvent in which the phase change material is dissolved and a surfactant. The coolant may further include a propellant to express the product from the aerosol container. In another aspect, an epidermal coolant includes a porous material and a phase change material retained in the porous material. The phase change material has a melting point between about 0-degrees Celsius and about 65-degrees Celsius and is retained in the porous material when the phase change material is in either the solid or liquid phase.

Abstract: In one aspect, an epidermal coolant includes a porous material and a phase change material retained in the porous material. The phase change material has a melting point between about 0-degrees Celsius and about 65-degrees Celsius and is retained in the porous material when the phase change material is in either the solid or liquid phase. In another aspect, an epidermal coolant dispensable by an aerosol container includes a phase change material that changes phase between about 28-degrees and 40-degrees Celsius. The coolant also includes a solvent in which the phase change material is dissolved and a surfactant. The coolant may further include a propellant to express the product from the aerosol container.

Abstract: A stack of folded web substrates is disclosed. Each folded web substrate has a folded surface area of about A/8 produced from a respective unfolded web substrate having an unfolded surface area of A and having a lotion applied to one surface thereof. The stack of folded web substrates has a normalized Mellin gauge value of greater than 0.06.

Abstract: A cooling sensation agent composition with a prolonged cool sensation effect is provided comprising at least one compound selected from the group consisting of aceia or ketal derivatives of 3-(1-menthoxy)propan-1,2-diol represented by Formula (1), single or mixed carbonic esters ol one or two kinds ol alcohols represented by Formula (2), and carboxylic esters represented by Formula (4). A sensory stimulation agoni composition, a flavor or fragrance composition, a beverage or food product, a perfume or cosmetic product, a toiletry product, a daily utensil product or grocery, a fiber, a fiber product, a cloth or a medicine comprising the cooling sensation agent composition; a production method thereof; a cooling processing method of a fiber, fiber product or a cloth, comprising compounding the cooling sensation agent; and new compounds are also provided.

Abstract: The present invention provides drug-free adaptable aggregate compositions, typically having a form of bilayer vesicles suspended in a polar, optionally thickened, fluid comprising different pharmaceutically acceptable excipients for use in or on a mammal for any medical indication, specifically for non-invasive treatment of local inflammation and the associated pain, in particular for use on the skin and underlying tissues, including muscles and/or superficial joints. Accompanying guidelines for selecting components to thereby optimizing the formulations are also provided.

Abstract: A novel antiseptic agent composition which has a wide antimicrobial spectrum and excellent antiseptic properties is provided. An antiseptic agent composition A contains a glycerin hydroxy fatty acid monoester that is an ester of glycerin and a hydroxy fatty acid having 8 to 18 carbon atoms, and a specific antiseptic agent such as an alkanediol. An antiseptic agent composition B contains the glycerin hydroxy fatty acid monoester and an aromatic antiseptic agent. An antiseptic agent composition C contains the glycerin hydroxy fatty acid monoester and a chelating agent.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy, comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof, wherein the subject is not on concomitant omega-3 fatty acid therapy.

Abstract: Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15% by weight fatty acid moieties with carbon chain lengths of C18 or higher. Additives may be disposed in or on the hard cosmetic particles and delivered when the cosmetic particles are broken proximate a target such as the skin, hair or nails of a mammalian subject or another target. The transformable hard cosmetic particles permit the storage and shipment of intact cosmetic particles yet transform in situ to achieve the benefits of soft cosmetic particles.

Abstract: The present invention relates to a solid cosmetic composition comprising, as a structure agent, a combination consisting of a saturated straight-chain polymer and an agglutinating agent for this polymer. The composition of the invention has a rigid, moldable and stable structure, being suitable for application as, for example, lipstick, blush, eye shadow, stick base, lip protectors (either colorful or colorless), deodorants, perfumes, among others.

Abstract: The present invention relates to a composition comprising: (a) at least one alkoxylated polyamine; (b) at least one organic acid chosen from alkyl acids, alkoxylated monoacids, and mixtures thereof; (c) at least one lipophilic compound; and (d) at least one solvent comprising water. Such a composition is clear in appearance, and stable. The present invention also relates to a method of making such a clear composition, and to a method of cosmetic treatment of a keratinous substrate using such a composition.

Abstract: Biodegradable flavoring agent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable flavoring agent compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.

Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.

Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, an antimicrobial lipid component, such as a fatty acid ester, fatty ether, or alkoxide derivative thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).

Abstract: An object of the present invention is to provide an analgesic effective in a prophylactic or a therapy for various pain diseases. The present invention is to provide an analgesic containing an ester of C10 fatty acid as an active ingredient. The analgesic of the present invention containing the compound as an active ingredient is highly useful as a prophylactic or therapeutic agent for various pain diseases such as the pain caused by osteoarthritis (e.g., knee osteoarthritis and hip osteoarthritis) or by demyelinating diseases such as multiple sclerosis or Guillain-Bareé syndrome.

Abstract: Processes for obtaining aqueous dispersions comprising alcohols and acids obtained by hydrolysis of jojoba oil. Hydrolyzed jojoba oil products are treated by a process comprising neutralization of jojoba fatty acids with aliphatic organic amines dissolved in a co-solvent followed by the dispersion of both the neutralized fatty acids together with jojoba alcohols in an aqueous medium. The products obtained, generically named hydrolyzed jojoba oil (HJO), promote transdermal absorption and are useful vehicles for carrying a wide range of pharmaceutical and cosmetic compositions, including pharmaceutical and cosmetic compositions comprising either lipophilic or hydrophilic active principles. The HJO can also be used to produce a semisolid, self-emulsified jojoba oil (SEJO), obtained by emulsifying the HJO in jojoba oil.

Abstract: The present invention provides compositions and methods for topical treatment of infections. The compositions comprise glycerol monolaurate or a derivative thereof, and are administered topically, for example, to treat viral, fungal or bacterial infections.

Abstract: A personal care composition includes a cleansing phase and a benefit phase, the cleansing phase having a surfactant and the benefit phase having a lipid bilayer structurant. Methods to enhance skin hydration are also provided.

Abstract: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.

Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.

Abstract: The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.

Abstract: A process for treating psoriasis and similar skin disorders whereby two formulations are used. The first formulation in a cream, gel, lotion, foam or ointment base is used two or more times daily, and contains effective amounts of (but not limited to) methylcobalamin, niacinamide, select cetylated fatty esters, and antioxidants. This formulation is used to suppress immunoproliferative and inflammatory mediated activities that play significant roles in hyperproliferation and erythema. The second formulation, used selectively to reduce plaque thickening and to reduce irritation, contains effective amounts of (but not limited to) salicylic acid and select cetylated fatty esters in a cream, gel, lotion or ointment base, with pH optimized for exfoliation properties. The unique combination of salicylic acid (or other ?- or ?-hydroxy acid) and cetylated fatty esters provides keratolytic activity while suppressing irritation and inflammation.

Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, an antimicrobial lipid component, such as a fatty acid ester, fatty ether, or alkoxide derivative thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).

Abstract: The present invention is directed to compositions and processes for their use that ameliorate the appearance of bruises, making them less cosmetically unappealing. The composition functions by acting both as a humectant and occlusive agent attracting water, returning the skin surface to a smooth state and holding water in place. The re-establishment of a homeostatic state in the skin results in a rapid dissipation of the negative cosmetic effects of the bruise on the skin.

Abstract: A surfactant composition comprising the following elements in the indicated amounts expressed as percentage by weight: (a) 1 to 20% of at least one fatty acyl isethionate compound; (b) 0.1% to 10% of at least one acyl glycinate compound; (c) 0.1% to 20% of at least one alkyl betaine compound; and (d) 60% to 98.8% of water wherein the weight ratio of fatty acyl isethionate to acyl glycinate and alkyl betaine is in the range of 1:0.1 to 1:1 and the composition is clear, concentrated and flowable at and below 25° C. and pH at and below 6.

Abstract: A composition and method for promoting neutrophil survival and activation such as the treatment of neutropenia arising as an undesirable side effect of chemotherapy and radiation therapy. A composition containing medium-chain fatty acids, such as Capri acid or caprylic acid, or salts or triglycerides thereof, or mono- or diglycerides or other analogues thereof or medium-chain triglycerides (MCT) is administered to a human or animal needing treatment in an amount sufficient to reduce or eliminate neutropenia. The composition is administered in an amount effective to treat the disorder. The methods are also useful in the management of bone narrow transplantation and in the treatment of various neutropenic diseases.